[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUP0203597A2 - Zolmitriptant tartalmazó gyógyszerkészítmények, eljárás az előállításukra és alkalmazásuk - Google Patents

Zolmitriptant tartalmazó gyógyszerkészítmények, eljárás az előállításukra és alkalmazásuk

Info

Publication number
HUP0203597A2
HUP0203597A2 HU0203597A HUP0203597A HUP0203597A2 HU P0203597 A2 HUP0203597 A2 HU P0203597A2 HU 0203597 A HU0203597 A HU 0203597A HU P0203597 A HUP0203597 A HU P0203597A HU P0203597 A2 HUP0203597 A2 HU P0203597A2
Authority
HU
Hungary
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
zolmitriptan
subject
Prior art date
Application number
HU0203597A
Other languages
English (en)
Inventor
Trevor John Coomber
Alan Roy Dearn
Simon John Summers
Sarah Louise Williamson
Original Assignee
Astrazeneca Ab,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10865629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0203597(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, filed Critical Astrazeneca Ab,
Publication of HUP0203597A2 publication Critical patent/HUP0203597A2/hu
Publication of HUP0203597A3 publication Critical patent/HUP0203597A3/hu
Publication of HU229458B1 publication Critical patent/HU229458B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A találmány tárgyát az 5HT1-receptor agonista zolmitriptant és egygyógyszerészetileg elfogadható hordozót tartalmazó, intranazálisalkalmazásra felhasználható, 7,0 alatti pH-jú, előnyösen 4,5 és 5,5közötti pH-ra a citromsav és dinátrium-hidrogén-foszfát keverékénekvizes oldatával pufferolt, autoklávozással sterilizáltgyógyszerkészítmény képezi. A találmány tárgyát képezi továbbá a fentigyógyszerkészítményt tartalmazó, becsomagolással a fénytől védettporlasztó készülék, valamint a készítménynek az olyan betegségiállapot kezelésére való alkalmazása, amelyben az 5HT1-receptorokserkentése jótékony hatású. Ó
HU0203597A 1999-12-03 2000-11-28 Pharmaceutical compositions containing zolmitriptan HU229458B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9928578.5A GB9928578D0 (en) 1999-12-03 1999-12-03 Pharmaceutical formulations
PCT/GB2000/004528 WO2001039772A1 (en) 1999-12-03 2000-11-28 Pharmaceutical formulations containing zolmitriptan

Publications (3)

Publication Number Publication Date
HUP0203597A2 true HUP0203597A2 (hu) 2003-02-28
HUP0203597A3 HUP0203597A3 (en) 2005-07-28
HU229458B1 HU229458B1 (en) 2013-12-30

Family

ID=10865629

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203597A HU229458B1 (en) 1999-12-03 2000-11-28 Pharmaceutical compositions containing zolmitriptan

Country Status (28)

Country Link
US (2) US6750237B1 (hu)
EP (1) EP1237551B1 (hu)
JP (1) JP2003515559A (hu)
KR (1) KR100670092B1 (hu)
CN (1) CN1222287C (hu)
AT (1) ATE291914T1 (hu)
AU (1) AU778092B2 (hu)
BR (1) BRPI0016138B8 (hu)
CA (1) CA2392050C (hu)
CZ (1) CZ301528B6 (hu)
DE (1) DE60019162T2 (hu)
EE (1) EE05305B1 (hu)
ES (1) ES2236001T3 (hu)
GB (2) GB9928578D0 (hu)
HK (3) HK1048442B (hu)
HU (1) HU229458B1 (hu)
IL (2) IL149578A0 (hu)
IS (1) IS2135B (hu)
MX (1) MXPA02005319A (hu)
NO (1) NO322119B1 (hu)
NZ (1) NZ518862A (hu)
PL (1) PL200679B1 (hu)
PT (1) PT1237551E (hu)
RU (1) RU2255736C2 (hu)
SK (1) SK287228B6 (hu)
UA (1) UA75059C2 (hu)
WO (1) WO2001039772A1 (hu)
ZA (1) ZA200203704B (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
US20050256182A1 (en) * 2004-05-11 2005-11-17 Sutter Diane E Formulations of anti-pain agents and methods of using the same
WO2005115345A1 (en) * 2004-05-28 2005-12-08 Imaginot Pty Ltd Oral therapeutic compound delivery system
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP1812428A2 (en) * 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Zolmitriptan crystal forms
CN100341504C (zh) * 2004-12-01 2007-10-10 鲁南制药集团股份有限公司 佐米曲普坦速释制剂
EP3263117A1 (en) * 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
BRPI0715579A2 (pt) * 2006-10-19 2015-05-26 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
KR101517415B1 (ko) * 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
AU2011316225B2 (en) 2010-10-15 2016-05-19 Contera Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
JP6121734B2 (ja) * 2012-02-09 2017-04-26 久光製薬株式会社 マイクロニードル用ゾルミトリプタン含有コーティング組成物及びマイクロニードルデバイス
HUE037732T2 (hu) 2012-04-18 2018-09-28 Contera Pharma Aps A mozgászavarok fejlett kezelésére alkalmas, szájon át szedhetõ gyógyszerészeti készítmény
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
KR101624049B1 (ko) 2014-10-29 2016-05-24 연세대학교 산학협력단 사카린을 이용한 용해도를 증가시킨 약제학적 조성물
CN108135916B (zh) * 2015-06-19 2022-01-28 北京科辉智药生物科技有限责任公司 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用
WO2017122161A1 (en) 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
EP3481385A1 (en) 2016-07-11 2019-05-15 Contera Pharma APS Pulsatile drug delivery system for treating morning akinesia
WO2019126766A1 (en) * 2017-12-21 2019-06-27 Taiwan Liposome Co., Ltd. Sustained-release triptan compositions and method of use the same through subdermal route or the like
US20210322343A1 (en) 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ238424A (en) * 1990-06-07 1993-12-23 Wellcome Found 3,5-substituted indole derivatives; medicaments and preparatory processes.
JP2000505090A (ja) * 1996-07-11 2000-04-25 ファーマーク、ニーダーランド、ベスローテン、フェンノートシャップ インドール選択的セロトニンアゴニストを含む包接錯体
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
DE59804534D1 (de) * 1997-02-05 2002-07-25 Jago Res Ag Muttenz Medizinische aerosolformulierungen
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
US20040214899A1 (en) 2004-10-28
NZ518862A (en) 2004-02-27
SK7532002A3 (en) 2002-12-03
CZ301528B6 (cs) 2010-04-07
NO20022525D0 (no) 2002-05-28
EP1237551B1 (en) 2005-03-30
HUP0203597A3 (en) 2005-07-28
HK1048442A1 (en) 2003-04-04
ATE291914T1 (de) 2005-04-15
IL149578A (en) 2008-04-13
IL149578A0 (en) 2002-11-10
NO322119B1 (no) 2006-08-14
KR20020058051A (ko) 2002-07-12
GB2373726A (en) 2002-10-02
MXPA02005319A (es) 2002-12-06
RU2255736C2 (ru) 2005-07-10
HU229458B1 (en) 2013-12-30
EP1237551A1 (en) 2002-09-11
HK1048442B (zh) 2005-05-13
BR0016138B1 (pt) 2013-09-10
US6750237B1 (en) 2004-06-15
PT1237551E (pt) 2005-07-29
PL357597A1 (en) 2004-07-26
ZA200203704B (en) 2003-10-29
NO20022525L (no) 2002-05-28
DE60019162D1 (de) 2005-05-04
CA2392050A1 (en) 2001-06-07
DE60019162T2 (de) 2006-02-02
KR100670092B1 (ko) 2007-01-17
GB2373726B (en) 2004-10-20
HK1048445A1 (en) 2003-04-04
BR0016138A (pt) 2002-08-06
RU2002117649A (ru) 2004-01-27
AU1715701A (en) 2001-06-12
JP2003515559A (ja) 2003-05-07
IS6394A (is) 2002-05-24
GB0214845D0 (en) 2002-08-07
SK287228B6 (sk) 2010-03-08
IS2135B (is) 2006-08-15
GB9928578D0 (en) 2000-02-02
HK1048445B (zh) 2005-08-26
HK1053430A1 (en) 2003-10-24
UA75059C2 (uk) 2006-03-15
PL200679B1 (pl) 2009-01-30
CA2392050C (en) 2009-11-24
AU778092B2 (en) 2004-11-18
CN1402636A (zh) 2003-03-12
US7220767B2 (en) 2007-05-22
CN1222287C (zh) 2005-10-12
CZ20021901A3 (cs) 2002-11-13
EE05305B1 (et) 2010-06-15
WO2001039772A1 (en) 2001-06-07
ES2236001T3 (es) 2005-07-16
EE200200283A (et) 2003-06-16
BRPI0016138B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
HUP0203597A2 (hu) Zolmitriptant tartalmazó gyógyszerkészítmények, eljárás az előállításukra és alkalmazásuk
HUP0203325A2 (hu) Biciklusos aminosavak, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CO4600739A1 (es) Formulaciones liquidas orales a base de alendronato
HUP0001089A2 (hu) Gyógyászati készítmények férfiak erekciós zavarainak kezelésére
CY1108672T1 (el) Φαρμακευτικη συσκευασια προϊοντος δια μικροβιοκτονο θεραπεια
BR0214757A (pt) Formulações farmacêuticas de derivados de platina
HUP0301349A2 (hu) IL-11-tartalmú készítmények
YU2494A (sh) Farmaceutska formulacija za tretiranje zavisnosti od nikotina
MA27702A1 (fr) Preparation de suspensions aqueuses steriles comprenant des ingredients actifs cristallins micronises, destinees a l'inhalation
HUP0402577A2 (hu) Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
HUP0204550A2 (en) Stable, nasally, orally or sublingually applicable pharmaceutical preparation and process for its preparation
SE0102440D0 (sv) New compound
HUP0301128A2 (hu) 5-Metil-2-(2'-kloro-6'-fluoranilino)-fenilecetsavat tartalmazó gyógyszerkészítmények ciklooxigenáz-2-vel kapcsolatos betegségek kezelésére és alkalmazásuk
DK1343472T3 (da) Thixotropisk næsespray
CY1106105T1 (el) Αλας μεγλουμινης ενος συγκεκριμενου κινολινοκαρβοξυλικου οξεως ενepγου επι των υποδοχεων nmda
HUP0300863A2 (hu) N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
HUP0204391A2 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
HUP0401234A2 (hu) Pravastatin stabil gyógyászati kompozíciója és eljárás az előállítására
ITMI932189A1 (it) Composizioni farmaceutiche contenenti n-acetilcarnosina per il trattamento della cataratta
HUP0200145A2 (hu) Tianeptin alkalmazása neurodegeneratív betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
HUP0302291A2 (hu) Szulfonamid származékok, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
TNSN05247A1 (en) Use of carbamazepine derivatives for the treatment of agitation in dementia patients
HUP9904030A2 (hu) Tiagabin felhasználása pszichotikus rendellenességek kezelésére alkalmas gyógyszer előállítására
EA200400691A1 (ru) Получение чистых стереоизомеров трицикло[5,2,1,02,6]дец-9-ил-ксантогената и содержащие их лекарственные средства
HUP0402654A2 (hu) 2-[(2'-Halogén-3',5'-dialkoxi-fenil)-imino]-imidazolidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények